menu
    • menu
    [{"orgOrder":0,"company":"Cellogen Therapeutics","sponsor":"Natco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellogen Therapeutics \/ Natco Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Cellogen Therapeutics \/ Natco Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellogen Therapeutics

    Menu

    Cellogen Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Cellogen Therapeutics

    India arrow
    BePharma
    Not Confirmed

    Cellogen Therapeutics

    India arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Undisclosed

    Sponsor : Natco Pharma

    Deal Size : $2.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    NATCO Invests US$ 2 Million in Cellogen Therapeutics

    Details : Proceeds will support the development of a chimeric antigen receptor T cell therapy program at Cellogen Therapeutics, genetically engineering T cells to target cancer cells.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    January 18, 2024

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Sponsor : Natco Pharma

    Deal Size : $2.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth